ZVRA earnings analysis
What we found in ZVRA's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Zevra Therapeutics reported a strong Q1 2026 with $36.2 million in revenue, up $15.8 million from the previous year, and a significant EPS of $0.60 compared to a loss of $0.06 in Q1 2025. The results were bolstered by increased product sales of its MIPLYFFA therapy and a notable gain from the sale of royalties. Overall, the company continues to strengthen its cash position with $236.8 million in liquidity, following its debt repayment and portfolio optimization efforts.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue Growth of 77.5%
- Q1 2026 revenue reached $36.2 million, a 77.5% increase from $20.4 million in Q1 2025.
- Strong EPS Performance
- Diluted EPS for Q1 2026 was $0.60 compared to a loss of $0.06 in the prior year, marking a $0.66 improvement.
- Debt-Free Balance Sheet
- Completed a $50 million asset sale, leading to a cash position of $236.8 million and repayment of $63.1 million in debt.
- Significant Gain on Asset Sale
- Reported a gain of $43.3 million on the sale of future royalties and assets under the Commave Settlement Agreement.
- Operating Cash Flow Positive
- Net cash provided by operating activities was $6.1 million in Q1 2026, compared to a negative $8.2 million in the prior year.
- Increased Focus on MIPLYFFA Success
- Revenue from MIPLYFFA increased by $7.5 million, enhancing future growth potential.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Loss on Extinguishment of Debt
- Reported a loss of $2.8 million associated with the repayment of debt in Q1 2026.
- Regulatory and Healthcare Reform Uncertainty
- New healthcare reforms may complicate reimbursement and approval processes for future products.
- Increased Operating Expenses
- Total operating expenses rose to $25.2 million from $22.8 million in the same quarter last year.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $0.6
- Segment
- MIPLYFFA: $7.5M increase in revenue
- Segment
- OLPRUVA: $0.3M revenue reported
What they said about what is next.
No forward guidance provided in the report.
The filing reads better than the one before it.
What came before.
- 10-K · March 9, 2026
- Zevra transitioned to a commercial-stage rare-disease company in 2025 driven by the launch of MIPLYFFA, producing substantial top-line growth and a sharp margin inflection in Q4. The company monetized a rare pediatric…
- 10-Q · May 13, 2025
- Zevra reported a large revenue ramp to $20,401 (in thousands) in Q1 2025 from $3,425 in Q1 2024, driving a marked improvement in reported EPS to $(0.06) from $(0.40). Gross margins remained high (93.4% on a comparable…
- 10-K · March 12, 2025
- Zevra is a commercial-stage rare-disease company that launched MIPLYFFA (arimoclomol) after FDA approval on September 20, 2024 and made product commercially available November 21, 2024, while continuing…
- 10-Q · November 13, 2024
- Zevra reported Q3 revenue of $3.695M (up $0.800M, +27.6% vs Q3 2023) but posted a GAAP net loss of $33.225M (‑$0.69 per share), driven by $1.545M of intangible amortization, a $1.545M increase in cost of goods and a…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing ZVRA makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever